HUTCHMED (NASDAQ:HCM) Trading Up 7.5% – Should You Buy?

HUTCHMED (China) Limited (NASDAQ:HCM) shares were up 7.5% during mid-day trading on Tuesday . The stock traded as high as $16.44 and last traded at $16.17. Approximately 64,171 shares changed hands during trading, a decline of 40% from the average daily volume of 106,190 shares. The stock had previously closed at $15.04.

Analyst Ratings Changes

Separately, StockNews.com raised HUTCHMED from a “hold” rating to a “buy” rating in a research note on Friday, March 21st.

HUTCHMED Stock Down 1.0 %

The company’s fifty day moving average is $14.85 and its 200-day moving average is $16.40. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.

Institutional Investors Weigh In On HUTCHMED

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio bought a new stake in HUTCHMED during the 3rd quarter valued at approximately $35,000. Barclays PLC boosted its position in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock valued at $35,000 after acquiring an additional 2,255 shares during the period. Blue Trust Inc. grew its stake in shares of HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after acquiring an additional 3,532 shares during the last quarter. Summit Trail Advisors LLC increased its position in HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after acquiring an additional 1,647 shares during the period. Finally, OLD Mission Capital LLC acquired a new position in HUTCHMED during the 4th quarter valued at $230,000. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.